Dr. Ron DeMatteo GIST specialist surgeon Dr. Ron DeMatteo, along with colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC), has published a new paper in the April issue of Cancer Research with potentially [...]
Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
A recent nonrandomized study has shown that imatinib rechallenge impacted the survival rate for patients with advanced or metastatic gastrointestinal stromal tumor (GIST).
Many GIST patients use a Proton-pump inhibitor (PPI) to combat the side effects of nausea and acid reflux. PPI's help treat gastroesophageal reflux disease, or GERD, when stomach acid backs up into the esophagus. Three [...]
With the advent of Imatinib, tremendous progress has been made in the treatment of patients with GIST.
Breaking Research Barriers! The Life Raft Group Research Team is unique. As we know, the purpose of research is to inform, educate and allow us to live better lives.
Resecting GIST tumors may improve survival rates. Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
Here is a presentation from Life Fest 2012 by Michael Heinrich, M.D. titled GIST: From Pathology Puzzle to Targeted Therapy.
